Doctors Favor CPAP, Patients Favor Tirzepatide for Comorbid Obesity, Sleep Apnea

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on June 9, 2025.

By Elana Gotkine HealthDay Reporter

MONDAY, June 9, 2025 -- Both continuous positive airway pressure (CPAP) and tirzepatide are acceptable treatments for comorbid obesity and obstructive sleep apnea (COBOSA), with providers favoring CPAP and patients preferring tirzepatide, according to a study presented at SLEEP 2025, the annual meeting of the Associated Professional Sleep Societies, held from June 8 to 11 in Seattle.

Ahmed Khalaf, from the University of California, San Diego, and colleagues examined patient and provider attitudes toward use of CPAP and tirzepatide for COBOSA using an online survey. The survey was distributed to 17 sleep medicine providers and about 6,500 patients aged 21 years or older seen at a sleep clinic in the preceding two years.

Seventeen providers and 365 patients responded to the survey. The researchers found that 53 percent of patients had COBOSA; 23 percent had current/past use of tirzepatide and/or semaglutide, and 78 percent had current/past use of CPAP. The researchers found that more than 75 percent of patients and providers reported that CPAP and tirzepatide were somewhat/very acceptable. Similar acceptability was reported by patients for both therapies, while for CPAP, providers were more accepting than patients (88 versus 59 percent reported CPAP as very acceptable). If evidence demonstrated equal effectiveness, patients leaned toward tirzepatide (48 versus 35 percent), while providers favored CPAP (53 versus 26 percent). Combination therapy was supported by both groups, but patients were less enthusiastic (61 versus 88 percent).

"Understanding these differences is critical for shared decision-making throughout the care plan, which may ultimately impact adherence and treatment success," Khalaf said in a statement.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-06-10 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords